Remove Biotech Remove Competitive Remove Market Intelligence
article thumbnail

Key Takeaways from J.P. Morgan’s 41st Annual Healthcare Conference?

Alpha Sense BI

Specifically, within the pharma and biotech sectors, there have been 22 deals announced so far in 2023 — again, a low number compared to the 70 made over the same period last year. Additionally, unprofitable biopharma, aka most biotech companies, is expected to invest $1.1

Biotech 96
article thumbnail

The Evolution of AI in Asset Management

Alpha Sense BI

As time goes on and more firms adopt AI tools, these capabilities will become even more essential to maintain a competitive advantage. Research shows that the AI in asset management market will grow at a staggering 34% CAGR through 2027. Artificial intelligence is the only way to do it.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Slow Start to Venture Capital Funding in 2024

Alpha Sense BI

Below, we explore the factors constraining venture capital funding into the first half of the year, and the ways investors can leverage crucial market intelligence to gain a competitive advantage in the shifting landscape. Investors funded $76 billion in the period, their lowest since the second quarter of 2019.

Capital 69
article thumbnail

Venture Capital Trends and Outlook for 2024

Alpha Sense BI

Market Analysis : A valuable tool for conducting market research , as it can analyze large volumes of market data, predict market trends, analyze customer preferences, and provide a snapshot of the competitive landscape. Competition for fundraising will continue heating up among startup companies in 2024.

Capital 52
article thumbnail

What to Know About Medicare Drug Price Negotiations

Alpha Sense BI

The 10 initial drugs were chosen based on certain criteria set out by Medicare: they must be sold in pharmacies, not have substantial generic competition , and have been on the market for at least nine to 13 years for more complex biotech drugs.

article thumbnail

M&A in Healthcare: 2024 Outlook

Alpha Sense BI

billion acquisition of Carmot Therapeutics, a clinical-stage biotechnology company with three GLP-1 assets in clinical production, including its CT-388 lead GLP-1 asset, in the hopes of gaining a competitive footing among Novo Nordisk and Eli Lilly’s products currently on the market (Ozempic, Wegovy, and Mounjaro, respectively).

article thumbnail

Technology Industry Trends and Outlook in 2024

Alpha Sense BI

2023 was all about learning the use cases of genAI, as companies raced to introduce their own genAI offerings and capabilities into a fiercely competitive market (i.e. trillion market evaluation by 2032 due to the ever-increasing number of companies integrating this technology. OpenAI’s ChatGPT ). Start your free trial today.